Macrophage-mediated proteolytic remodeling of the extracellular matrix in atherosclerosis results in neoepitopes: A potential new class of biochemical markers

Assay and Drug Development Technologies

Volumn 8, Issue 5, 2010, Pages 542-552

  Skjøt Arkil, Helene ^a,b   Barascuk, Natasha ^a,b   Register, Thomas ^c   Karsdal, Morten A ^a  

^a NORDIC BIOSCIENCE A S   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAMTS1 PROTEIN; AGGRECANASE; BIOCHEMICAL MARKER; C REACTIVE PROTEIN; CATHEPSIN; CATHEPSIN B; CATHEPSIN H; CATHEPSIN K; CATHEPSIN L; CATHEPSIN S; COLLAGEN TYPE 1; COLLAGEN TYPE 2; COLLAGEN TYPE 3; COLLAGEN TYPE 5; COLLAGENASE 3; ELASTIN; EPITOPE; GELATINASE A; GELATINASE B; INTERLEUKIN 6; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE; NEUTROPHIL COLLAGENASE; PHOSPHOLIPASE A2; PROTEINASE; PROTEOGLYCAN; STROMELYSIN; STROMELYSIN 2; STROMELYSIN 3; UNINDEXED DRUG;

ARTERY WALL; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; ENZYME RELEASE; EXTRACELLULAR MATRIX; FOAM CELL; HEART INFARCTION; HUMAN; MACROPHAGE; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PROTEIN DEGRADATION; REVIEW;

ARTERIES; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CARDIOVASCULAR SYSTEM; COLLAGEN; COLLAGENASES; ELASTIN; ENDOPEPTIDASES; EPITOPES; EXTRACELLULAR MATRIX; FEMALE; FOAM CELLS; HUMANS; MACROPHAGES; MALE; MATRIX METALLOPROTEINASES; PEPTIDE HYDROLASES; PLAQUE, ATHEROSCLEROTIC;

EID: 77958608538     PISSN: 1540658X     EISSN: None     Source Type: Journal    
DOI: 10.1089/adt.2009.0258     Document Type: Review

References (110)

1. Petersen S, Peto V, Rayner M, Leal J, Luengo-Fernandez R, Gray A: European cardiovascular disease statistics. 2008. The European Heart Network & The British Heart Foundation. www.heartstats.org/datapage.asp?id=7683 [accessed 03/06/2010]
2. De Backer G, Ambrosioni E, Borch-Johnsen K, et al.: European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts). Atherosclerosis 2004;173:381-391.
3. Sundstrom J, Vasan RS: Circulating biomarkers of extracellular matrix remodeling and risk of atherosclerotic events. Curr Opin Lipidol 2006;17:45-53.
4. Koenig W, Khuseyinova N: Biomarkers of atherosclerotic plaque instability and rupture. Arterioscler Thromb Vasc Biol 2007;27:15-26.
5. Gerszten RE, Wang TJ: The search for new cardiovascular biomarkers. Nature 2008;451:949-952.
6. Adiguzel E, Ahmad PJ, Franco C, Bendeck MP: Collagens in the progression and complications of atherosclerosis. Vasc Med 2009;14:73-89.
7. Loscalzo J: Molecular Mechanisms of Atherosclerosis. Taylor & Francis, London, 2000.
8. Libby P: Inflammation and cardiovascular disease mechanisms. Am J Clin Nutr 2006;83:456S-460S.
9. Gu L, Okada Y, Clinton SK, et al.: Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell 1998;2:275-281.
10. Boring L, Gosling J, Cleary M, Charo IF: Decreased lesion formation in CCR2-/-mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 1998;394:894-897.
11. Choudhury RP, Lee JM, Greaves DR: Mechanisms of disease: macrophage-derived foam cells emerging as therapeutic targets in atherosclerosis. Nat Clin Pract Cardiovasc Med 2005;2:309-315.
12. Takahashi K, Takeya M, Sakashita N: Multifunctional roles of macrophages in the development and progression of atherosclerosis in humans and experimental animals. Med Electron Microsc 2002;35:179-203.
13. Li AC, Glass CK: The macrophage foam cell as a target for therapeutic intervention. Nat Med 2002;8:1235-1242.
14. Wagsater D, Bjork H, Zhu C, et al.: ADAMTS-4 and -8 are inflammatory regulated enzymes expressed in macrophage-rich areas of human atherosclerotic plaques. Atherosclerosis 2008;196:514-522.
15. Brauer PR: MMPs-role in cardiovascular development and disease. Front Biosci 2006;11:447-478.
16. Whatling C, Bjork H, Gredmark S, Hamsten A, Eriksson P: Effect of macrophage differentiation and exposure to mildly oxidized LDL on the proteolytic repertoire of THP-1 monocytes. J Lipid Res 2004;45:1768-1776.
17. Li AC, Glass CK: The macrophage foam cell as a target for therapeutic intervention. Nat Med 2002;8:1235-1242.
18. van Berkel TJ, Out R, Hoekstra M, Kuiper J, Biessen E, van EM: Scavenger receptors: friend or foe in atherosclerosis? Curr Opin Lipidol 2005;16: 525-535.
19. Greaves DR, Gordon S: Thematic review series: the immune system and atherogenesis. Recent insights into the biology of macrophage scavenger receptors. J Lipid Res 2005;46:11-20.
20. Shashkin P, Dragulev B, Ley K: Macrophage differentiation to foam cells. Curr Pharm Des 2005;11:3061-3072.
21. Nagornev VA, Maltseva SV: The phenotype of macrophages which are not transformed into foam cells in atherogenesis. Atherosclerosis 1996;121:245-251.
22. Shiffman D, Mikita T, Tai JT, et al.: Large scale gene expression analysis of cholesterol-loaded macrophages. J Biol Chem 2000;275:37324-37332.
23. Katsuda S, Kaji T: Atherosclerosis and extracellular matrix. J Atheroscler Thromb 2003;10:267-274.
24. Suzuki K, Enghild JJ, Morodomi T, Salvesen G, Nagase H: Mechanisms of activation of tissue procollagenase by matrix metalloproteinase 3 (stromelysin). Biochemistry 1990;29:10261-10270. (Pubitemid 20384533)
25. Lijnen HR: Plasmin and matrix metalloproteinases in vascular remodeling. Thromb Haemost 2001;86:324-333.
26. Gustafsson M, Boren J: Mechanism of lipoprotein retention by the extracellular matrix. Curr Opin Lipidol 2004;15:505-514.
27. Lipinski MJ, Frias JC, Fayad ZA: Advances in detection and characterization of atherosclerosis using contrast agents targeting the macrophage. J Nucl Cardiol 2006;13:699-709.
28. Moreno PR, Falk E, Palacios IF, Newell JB, Fuster V, Fallon JT: Macrophage infiltration in acute coronary syndromes. Implications for plaque rupture. Circulation 1994;90:775-778.
29. van der Wal AC, Becker AE, van der Loos CM, Tigges AJ, Das PK: Fibrous and lipid-rich atherosclerotic plaques are part of interchangeable morphologies related to inflammation: a concept. Coron Artery Dis 1994;5:463-469.
30. van der Wal AC, Becker AE, van der Loos CM, Das PK: Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 1994;89:36-44.
31. Veidal SS, Bay-Jensen AC, Tougas G, Karsdal MA, Vainer B: Serum markers of liver fibrosis: combining the BIPED classification and the neo-epitope approach in the development of new biomarkers. Dis Markers 2010;28:15-28.
32. Newby AC: Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol Rev 2005;85:1-31.
33. Bobryshev YV: Calcification of elastic fibers in human atherosclerotic plaque. Atherosclerosis 2005;180:293-303.
34. Rouis M: Matrix metalloproteinases: a potential therapeutic target in atherosclerosis. Curr Drug Targets Cardiovasc Haematol Disord 2005;5: 541-548.
35. Bode MK, Mosorin M, Satta J, Risteli L, Juvonen T, Risteli J: Complete processing of type III collagen in atherosclerotic plaques. Arterioscler Thromb Vasc Biol 1999;19:1506-1511.
36. Rekhter MD: Collagen synthesis in atherosclerosis: too much and not enough. Cardiovasc Res 1999;41:376-384.
37. Mayne R: Collagenous proteins of blood vessels. Arteriosclerosis 1986;6: 585-593.
38. Katsuda S, Okada Y, Minamoto T, Oda Y, Matsui Y, Nakanishi I: Collagens in human atherosclerosis. Immunohistochemical analysis using collagen type-specific antibodies. Arterioscler Thromb 1992;12:494-502.
39. Eriksen HA, Satta J, Risteli J, Veijola M, Vare P, Soini Y: Type I and type III collagen synthesis and composition in the valve matrix in aortic valve stenosis. Atherosclerosis 2006;189:91-98.
40. Barnes MJ, Farndale RW: Collagens and atherosclerosis. Exp Gerontol 1999;34:513-525.
41. Shekhonin BV, Domogatsky SP, Muzykantov VR, Idelson GL, Rukosuev VS: Distribution of type I, III, IV and V collagen in normal and atherosclerotic human arterial wall: immunomorphological characteristics. Coll Relat Res 1985;5:355-368.
42. McCullagh KG, Duance VC, Bishop KA: The distribution of collagen types I, III and V (AB) in normal and atherosclerotic human aorta. J Pathol 1980;130: 45-55.
43. Prockop DJ, Kivirikko KI: Collagens: molecular biology, diseases, and potentials for therapy. Annu Rev Biochem 1995;64:403-434.
44. Garrone R, Lethias C, Le Guellec D: Distribution of minor collagens during skin development. Microsc Res Tech 1997;38:407-412.
45. Ciornei CD, Tapper H, Bjartell A, Sternby NH, Bodelsson M: Human antimicrobial peptide LL-37 is present in atherosclerotic plaques and induces death of vascular smooth muscle cells: a laboratory study. BMC Cardiovasc Disord 2006;6:49.
46. Clarkson TB, Kaplan JR: Stage of reproductive life, atherosclerosis progression and estrogen effects on coronary artery atherosclerosis. In: Treatment of the Postmenopausal Woman: Basic and Clinical Aspects (Lobo RA, ed., 3rd ed.), Elsevier, San Diego, 2007;509-528.
47. Mecham RP, Broekelmann TJ, Fliszar CJ, Shapiro SD, Welgus HG, Senior RM: Elastin degradation by matrix metalloproteinases. Cleavage site specificity and mechanisms of elastolysis. J Biol Chem 1997;272:18071-18076.
48. Kielty CM, Sherratt MJ, Shuttleworth CA: Elastic fibres. J Cell Sci 2002;115(Pt 14):2817-2828.
49. Karnik SK, Brooke BS, Bayes-Genis A, et al.: A critical role for elastin signaling in vascular morphogenesis and disease. Development 2003;130:411-423.
50. Proudfoot D, Shanahan CM: Biology of calcification in vascular cells: intima versus media. Herz 2001;26:245-251.
51. Robert L, Robert AM, Jacotot B: Elastin-elastase-atherosclerosis revisited. Atherosclerosis 1998;140:281-295.
52. Wight TN: Cell biology of arterial proteoglycans. Arteriosclerosis 1989;9:1-20.
53. O'Brien KD, Olin KL, Alpers CE, et al.: Comparison of apolipoprotein and proteoglycan deposits in human coronary atherosclerotic plaques: colocalization of biglycan with apolipoproteins. Circulation 1998;98:519-527.
54. Kunz J: Matrix metalloproteinases and atherogenesis in dependence of age. Gerontology 2007;53:63-73.
55. Wight TN, Merrilees MJ: Proteoglycans in atherosclerosis and restenosis: key roles for versican. Circ Res 2004;94:1158-1167.
56. Sondergaard BC, Henriksen K, Wulf H, et al.: Relative contribution of matrix metalloprotease and cysteine protease activities to cytokine-stimulated articular cartilage degradation. Osteoarthritis Cartilage 2006;14: 738-748.
57. Kuzuya M, Nakamura K, Sasaki T, Cheng XW, Itohara S, Iguchi A: Effect of MMP-2 deficiency on atherosclerotic lesion formation in apoE-deficient mice. Arterioscler Thromb Vasc Biol 2006;26:1120-1125.
58. Gough PJ, Gomez IG, Wille PT, Raines EW: Macrophage expression of active MMP-9 induces acute plaque disruption in apoE-deficient mice. J Clin Invest 2006;116:59-69.
59. Sukhova GK, Shi GP: Do cathepsins play a role in abdominal aortic aneurysm pathogenesis? Ann N Y Acad Sci 2006;1085:161-169.
60. Sukhova GK, Shi GP, Simon DI, Chapman HA, Libby P: Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells. J Clin Invest 1998;102:576-583.
61. Sukhova GK, Zhang Y, Pan JH, et al.: Deficiency of cathepsin S reduces atherosclerosis in LDL receptor-deficient mice. J Clin Invest 2003;111: 897-906.
62. Novinec M, Grass RN, Stark WJ, Turk V, Baici A, Lenarcic B: Interaction between human cathepsins K, L, and S and elastins: mechanism of elastinolysis and inhibition by macromolecular inhibitors. J Biol Chem 2007; 282:7893-7902.
63. Lutgens SP, Cleutjens KB, Daemen MJ, Heeneman S: Cathepsin cysteine proteases in cardiovascular disease. FASEB J 2007;21:3029-3041. (Pubitemid 47565524)
64. Lutgens E, Lutgens SP, Faber BC, et al.: Disruption of the cathepsin K gene reduces atherosclerosis progression and induces plaque fibrosis but accelerates macrophage foam cell formation. Circulation 2006;113:98-107.
65. Liu J, Sukhova GK, Sun JS, Xu WH, Libby P, Shi GP: Lysosomal cysteine proteases in atherosclerosis. Arterioscler Thromb Vasc Biol 2004;24:1359-1366.
66. Jaffer FA, Kim DE, Quinti L, et al.: Optical visualization of cathepsin K activity in atherosclerosis with a novel, protease-activatable fluorescence sensor. Circulation 2007;115:2292-2298.
67. Garcia-Touchard A, Henry TD, Sangiorgi G, et al.: Extracellular proteases in atherosclerosis and restenosis. Arterioscler Thromb Vasc Biol 2005;25: 1119-1127.
68. Chen J, Tung CH, Mahmood U, et al.: In vivo imaging of proteolytic activity in atherosclerosis. Circulation 2002;105:2766-2771.
69. Chapman HA, Riese RJ, Shi GP: Emerging roles for cysteine proteases in human biology. Annu Rev Physiol 1997;59:63-88.
70. Luttun A, Lutgens E, Manderveld A, et al.: Loss of matrix metalloproteinase-9 or matrix metalloproteinase-12 protects apolipoprotein E-deficient mice against atherosclerotic media destruction but differentially affects plaque growth. Circulation 2004;109:1408-1414.
71. Jonsson-Rylander AC, Nilsson T, Fritsche-Danielson R, et al.: Role of ADAMTS-1 in atherosclerosis: remodeling of carotid artery, immunohistochemistry, and proteolysis of versican. Arterioscler Thromb Vasc Biol 2005;25:180-185.
72. Rouis M, Adamy C, Duverger N, et al.: Adenovirus-mediated overexpression of tissue inhibitor of metalloproteinase-1 reduces atherosclerotic lesions in apolipoprotein E-deficient mice. Circulation 1999;100:533-540.
73. Allaire E, Forough R, Clowes M, Starcher B, Clowes AW: Local overexpression of TIMP-1 prevents aortic aneurysm degeneration and rupture in a rat model. J Clin Invest 1998;102:1413-1420.
74. Rouis M: Matrix metalloproteinases: a potential therapeutic target in atherosclerosis. Curr Drug Targets Cardiovasc Haematol Disord 2005;5: 541-548.
75. Bailey M, Pillarisetti S, Jones P, Xiao H, Simionescu D, Vyavahare N: Involvement of matrix metalloproteinases and tenascin-C in elastin calcification. Cardiovasc Pathol 2004;13:146-155.
76. Xu XP, Meisel SR, Ong JM, et al.: Oxidized low-density lipoprotein regulates matrix metalloproteinase-9 and its tissue inhibitor in human monocyte-derived macrophages. Circulation 1999;99:993-998.
77. Eldrup N, Gronholdt ML, Sillesen H, Nordestgaard BG: Elevated matrix metalloproteinase-9 associated with stroke or cardiovascular death in patients with carotid stenosis. Circulation 2006;114:1847-1854.
78. Kuzuya M, Nakamura K, Sasaki T, Cheng XW, Itohara S, Iguchi A: Effect of MMP-2 deficiency on atherosclerotic lesion formation in apoE-deficient mice. Arterioscler Thromb Vasc Biol 2006;26:1120-1125.
79. Yamada Y, Izawa H, Ichihara S, et al.: Prediction of the risk of myocardial infarction from polymorphisms in candidate genes. N Engl J Med 2002; 347:1916-1923.
80. Silence J, Lupu F, Collen D, Lijnen HR: Persistence of atherosclerotic plaque but reduced aneurysm formation in mice with stromelysin-1 (MMP-3) gene inactivation. Arterioscler Thromb Vasc Biol 2001;21:1440-1445.
81. Herman MP, Sukhova GK, Libby P, et al.: Expression of neutrophil collagenase (matrix metalloproteinase-8) in human atheroma: a novel collagenolytic pathway suggested by transcriptional profiling. Circulation 2001;104: 1899-1904.
82. Molloy KJ, Thompson MM, Jones JL, et al.: Unstable carotid plaques exhibit raised matrix metalloproteinase-8 activity. Circulation 2004;110: 337-343.
83. Sukhova GK, Schönbeck U, Rabkin E, et al.: Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques. Circulation 1999;99:2503-2509.
84. Knauper V, Lopez-Otin C, Smith B, Knight G, Murphy G: Biochemical characterization of human collagenase-3. J Biol Chem 1996;271:1544-1550.
85. Turu MM, Krupinski J, Catena E, et al.: Intraplaque MMP-8 levels are increased in asymptomatic patients with carotid plaque progression on ultrasound. Atherosclerosis 2006;187:161-169.
86. Shapiro SD: Elastolytic metalloproteinases produced by human mononuclear phagocytes. Potential roles in destructive lung disease. Am J Respir Crit Care Med 1994;150(6Pt 2):S160-S164.
87. Beaudeux JL, Giral P, Bruckert E, Foglietti MJ, Chapman MJ: Matrix metalloproteinases, inflammation and atherosclerosis: therapeutic perspectives. Clin Chem Lab Med 2004;42:121-131.
88. Yamada S, Wang KY, Tanimoto A, et al.: Matrix metalloproteinase 12 accelerates the initiation of atherosclerosis and stimulates the progression of fatty streaks to fibrous plaques in transgenic rabbits. Am J Pathol 2008;172: 1419-1429.
89. Tang BL: ADAMTS: a novel family of extracellular matrix proteases. Int J Biochem Cell Biol 2001;33:33-44.
90. Wight TN: The ADAMTS proteases, extracellular matrix, and vascular disease: waking the sleeping giant(s)! Arterioscler Thromb Vasc Biol 2005;25:12-14.
91. Wagsater D, Bjork H, Zhu C, et al.: ADAMTS-4 and -8 are inflammatory regulated enzymes expressed in macrophage-rich areas of human atherosclerotic plaques. Atherosclerosis 2008;196:514-522.
92. Lalmanach G, Diot E, Godat E, Lecaille F, Herve-Grepinet V: Cysteine cathepsins and caspases in silicosis. Biol Chem 2006;387:863-870.
93. Lecaille F, Chowdhury S, Purisima E, Bromme D, Lalmanach G: The S2 subsites of cathepsins K and L and their contribution to collagen degradation. Protein Sci 2007;16:662-670.
94. Abdul-Hussien H, Soekhoe RG, Weber E, et al.: Collagen degradation in the abdominal aneurysm: a conspiracy of matrix metalloproteinase and cysteine collagenases. Am J Pathol 2007;170:809-817.
95. Hakala JK, Oksjoki R, Laine P, et al.: Lysosomal enzymes are released from cultured human macrophages, hydrolyze LDL in vitro, and are present extracellularly in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2003;23:1430-1436.
96. Sorensen MG, Henriksen K, Schaller S, et al.: Characterization of osteoclasts derived from CD14+ monocytes isolated from peripheral blood. J Bone Miner Metab 2007;25:36-45.
97. Karsdal MA, Hjorth P, Henriksen K, et al.: Transforming growth factor-beta controls human osteoclastogenesis through the p38 MAPK and regulation of RANK expression. J Biol Chem 2003;278:44975-44987.
98. Buhling F, Reisenauer A, Gerber A, et al.: Cathepsin K-a marker of macrophage differentiation? J Pathol 2001;195:375-382.
99. Samokhin AO, Wong A, Saftig P, Bromme D: Role of cathepsin K in structural changes in brachiocephalic artery during progression of atherosclerosis in apoE-deficient mice. Atherosclerosis 2008;200:58-68.
100. Zhen EY, Brittain IJ, Laska DA, et al.: Characterization of metalloprotease cleavage products of human articular cartilage. Arthritis Rheum 2008;58: 2420-2431.
101. Karsdal MA, Henriksen K, Leeming DJ, et al.: Biochemical markers and the FDA Critical Path: how biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development. Biomarkers 2009;14:181-202.
102. Schaller S, Henriksen K, Hoegh-Andersen P, et al.: In vitro, ex vivo, and in vivo methodological approaches for studying therapeutic targets of osteoporosis and degenerative joint diseases: how biomarkers can assist? Assay Drug Dev Technol 2005;3:553-580.
103. Schaller S, Henriksen K, Sveigaard C, et al.: The chloride channel inhibitor n53736 prevents bone resorption in ovariectomized rats without changing bone formation. J Bone Miner Res 2004;19:1144-1153.
104. Ravn P, Hosking D, Thompson D, et al.: Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study. J Clin Endocrinol Metab 1999;84: 2363-2368.
105. Nielsen RH, Stoop R, Leeming DJ, et al.: Evaluation of cartilage damage by measuring collagen degradation products in joint extracts in a traumatic model of osteoarthritis. Biomarkers 2008;13:79-87.
106. Reijman M, Hazes JM, Bierma-Zeinstra SM, et al.: A new marker for osteoarthritis: cross-sectional and longitudinal approach. Arthritis Rheum 2004;50:2471-2478.
107. Dam EB, Byrjalsen I, Karsdal MA, Qvist P, Christiansen C: Increased urinary excretion of C-telopeptides of type II collagen (CTX-II) predicts cartilage loss over 21 months by MRI. Osteoarthritis Cartilage 2009; 17:384-389.
108. Dam EB, Loog M, Christiansen C, et al.: Identification of progressors in osteoarthritis by combining biochemical and MRI-based markers. Arthritis Res Ther 2009;11:R115.
109. Bauer DC, Hunter DJ, Abramson SB, et al.: Classification of osteoarthritis biomarkers: a proposed approach. Osteoarthritis Cartilage 2006;14: 723-727.
110. Barascuk N, Zheng R, Wang J, et al.: A novel assay for assessment and quantification of arterial extracellular matrix remodeling in ApoE -/- mice. ESC Congress 2009 August 29th-September 2nd Abstract P4607. 29-8-0009.